1-3 of 3
Orit Itzhaki
Close
Sort by
Journal Articles

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Shalev Fried, Ivetta Danylesko, Ronit Marcus, Orit Itzhaki, Ronit Yerushalmi, Noga Shem-Tov, Inbal Sdayoor, Roni Shouval, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Abraham Avigdor
Journal: Blood
Blood (2023) 142 (Supplement 1): 6875.
https://doi.org/10.1182/blood-2023-178477
Published: 2023
Journal Articles

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

Inbal Sdayoor, Roni Shouval, Shalev Fried, Ronit Marcus, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Orit Itzhaki, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Michael J Segel, Abraham Avigdor
Journal: Blood
Blood (2023) 142 (Supplement 1): 3519.
https://doi.org/10.1182/blood-2023-180115
Published: 2023
Journal Articles

The Efficacy and Safety of Anti-CD19 CAR T-Cell Therapy in Young Adults with Relapsed and Refractory Aggressive B-Cell Malignancies—the Experience of a Single Center in Israel

Abraham Avigdor, MD, Michal Besser, PhD, Arnon Nagler, MD, Orit Itzhaki, PhD, Jacob Schachter, MD, Avichai Shimoni, MD, Ronit Yerushalmi, MD, Amos Toren, MD PhD, Elad Jacobi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5206.
https://doi.org/10.1182/blood.V130.Suppl_1.5206.5206
Published: 2017